On September 18, 2025, Contineum Therapeutics, Inc. reported positive topline data from a Phase 1b PET Trial of PIPE-791, showing significant receptor occupancy in patients, with target engagement demonstrated through plasma EC50 values of 37 ng/mL and 12 ng/mL at specified post-dose times. This is a significant event for the company from an equity investor perspective, reflecting a positive sentiment.